This is a proposal to identify clinically relevant modifiers of the severity of hepatic disease in patients with Alagille Syndrome (AGS) AGS is an autosomal dominant, multi-system, variably expressed disorder caused by mutations in one of two Notch Signaling Pathway genes. Mutations in Jagged1 (JAG1) are found in 95% of patients and mutations in Notch2 in less than 1%. AGS causes significant morbidity associated with liver, cardiac, renal and vascular malformations. The liver disease in AGS is characterized pathologically by intrahepatic bile duct paucity, with resulting cholestasis, and ranges from very mild (sub-clinical with only biochemical abnormalities of liver enzymes) to severe, in which case liver damage is extensive and a transplant is required. Mortality due to liver disease is about 5%. The highly variable expressivity is consistent with the presence of modifying factors that contribute to expressivity. We hypothesize that there are genetic modifiers of the severity of liver disease. We propose a multi-pronged approach to the identification of these genetic modifiers. Using our well-characterized cohort of patients with AGS and JAG1 mutations, we will compare patients with mild liver disease to patients with severe liver disease to look for evidence of genomic differences between the two groups. Recognizing the importance of attaining adequate power for the proposed studies, we will aggressively recruit additional patients. We will use multiple techniques to look for genetic differences between the patients with mild liver disease versus those with severe liver disease. We will test for association of copy number variants with liver disease severity. We will carry out a genome-wide association study using random tagSNPs and SNPs in specific genomic regions (candidate genes). We anticipate that identification of modifying factors for liver disease severity will have implications beyond Alagille syndrome patients, and may point to modifiers of liver disease severity in other disorders associated with cholestasis.
This project aims to identify modifiers of liver disease severity in Alagille syndrome. Severe liver disease in AGS is an important cause of liver transplantation, and 20% of AGS die as a result of liver disease. Identification of genetic factors associated with severe liver disease will have important implications for prognosis, and it is our hope that this will lead to improved therapies, as the pathways underlying liver disease progression are revealed. This may have implications for other cholestatic liver diseases as well.
|Leonard, Laura D; Chao, Grace; Baker, Alastair et al. (2014) Clinical utility gene card for: Alagille Syndrome (ALGS). Eur J Hum Genet 22:|
|Kamath, Binita M; Spinner, Nancy B; Rosenblum, Norman D (2013) Renal involvement and the role of Notch signalling in Alagille syndrome. Nat Rev Nephrol 9:409-18|
|Penton, Andrea L; Leonard, Laura D; Spinner, Nancy B (2012) Notch signaling in human development and disease. Semin Cell Dev Biol 23:450-7|
|Kamath, Binita Maya; Bauer, Robert C; Loomes, Kathleen M et al. (2012) NOTCH2 mutations in Alagille syndrome. J Med Genet 49:138-44|
|Lin, Henry C; Le Hoang, Phuc; Hutchinson, Anne et al. (2012) Alagille syndrome in a Vietnamese cohort: mutation analysis and assessment of facial features. Am J Med Genet A 158A:1005-13|